On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index, with changes to be implemented after market close on Friday, September 5th and taking effect from Monday, September 8th. The Shanghai and Shenzhen Stock Exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect program.

According to a research report by Huatai Securities, TRANSTHERA-B is likely to be included in the Hong Kong Stock Connect program as it meets a series of criteria including market capitalization, liquidity, and listing duration.

TRANSTHERA announced that its independently developed multi-target kinase inhibitor TT-00420 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that TT-00420 is currently a multi-target kinase inhibitor in global Phase III registration trials, which targets FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects. Clinical trials currently underway in the United States and China show that it has therapeutic potential in the treatment of various solid tumors.